| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.14 | $94.13 (0%) | 🛒 Add to cart |
| 60 | $2.27 | $188.26 $136.19 (28%) | 🛒 Add to cart |
| 90 | $1.97 | $282.40 $177.25 (37%) | 🛒 Add to cart |
| 120 | $1.84 | $376.53 $220.31 (41%) | 🛒 Add to cart |
| 180 | $1.69 | $564.79 $303.43 (46%) | 🛒 Add to cart |
| 270 | $1.58
Best per pill | $847.19 $427.60 (50%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.80 | $54.08 (0%) | 🛒 Add to cart |
| 60 | $1.37 | $108.15 $82.12 (24%) | 🛒 Add to cart |
| 90 | $1.22 | $162.23 $110.15 (32%) | 🛒 Add to cart |
| 120 | $1.15 | $216.30 $138.19 (36%) | 🛒 Add to cart |
| 180 | $1.08 | $324.46 $194.27 (40%) | 🛒 Add to cart |
| 270 | $1.03 | $486.68 $278.39 (43%) | 🛒 Add to cart |
| 360 | $1.00
Best per pill | $648.91 $360.51 (44%) | 🛒 Add to cart |
Synonyms | |||
More info:
Luvox: Effective OCD and Anxiety Symptom Management - Evidence-Based Review
Fluvoxamine, marketed under the brand name Luvox among others, is a selective serotonin reuptake inhibitor (SSRI) primarily prescribed for obsessive-compulsive disorder (OCD) and off-label for several anxiety-related conditions. It works by increasing serotonin levels in the brain, which helps regulate mood, anxiety, and obsessive thoughts. Available in tablet and extended-release capsule forms, it’s a cornerstone in psychopharmacology for its efficacy and relatively well-tolerated profile compared to older antidepressants. 1. Introduction: What is Luvox?
clozaril
Clozaril represents one of the most clinically significant yet challenging interventions in modern psychiatry. As an atypical antipsychotic medication (not a supplement or device), its proper name is clozapine, marketed under brands including Clozaril. It’s reserved specifically for treatment-resistant schizophrenia—cases where at least two other antipsychotics have failed—and for reducing suicide risk in schizophrenia or schizoaffective disorder. What makes it remarkable isn’t just efficacy, but the complex risk management surrounding its use.
cymbalta
Duloxetine hydrochloride, marketed under the brand name Cymbalta, represents a significant class of medication known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It’s not a dietary supplement or a medical device in the traditional sense, but a prescription pharmaceutical primarily indicated for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), among other conditions. Its development was a pivotal moment in psychopharmacology, offering a dual mechanism that distinguished it from the selective serotonin reuptake inhibitors (SSRIs) that dominated the market.
Daliresp: Reducing COPD Exacerbations Through Novel Anti-inflammatory Action
Daliresp, known generically as roflumilast, represents one of those interesting therapeutic agents that doesn’t fit neatly into traditional medication categories. It’s technically classified as a selective phosphodiesterase-4 (PDE4) inhibitor, but in practical terms, we use it primarily as an anti-inflammatory agent for specific chronic respiratory conditions. What makes daliresp particularly fascinating is its mechanism—it doesn’t work like bronchodilators that provide immediate relief, but rather modulates the underlying inflammatory processes that drive disease progression.
esbriet
Pirfenidone, marketed under the brand name Esbriet, represents a significant advancement in the management of idiopathic pulmonary fibrosis (IPF). This orally administered antifibrotic agent specifically targets the underlying pathological processes driving progressive lung scarring. Unlike traditional anti-inflammatory approaches that showed limited efficacy in IPF, Esbriet’s mechanism directly addresses the complex cytokine and growth factor signaling responsible for fibroblast proliferation and collagen deposition. The development journey spanned nearly two decades, with initial research focusing on its broad antifibrotic properties before narrowing to pulmonary applications.
melatonin
Melatonin, an endogenous neurohormone synthesized primarily by the pineal gland, represents one of the most fascinating compounds in chronobiology. Its primary role in regulating circadian rhythms and sleep-wake cycles has been understood for decades, but recent research has uncovered complex interactions with immune function, oxidative stress pathways, and even oncological processes. What began as a simple “sleep hormone” has evolved into a multifaceted therapeutic agent with applications spanning multiple medical specialties.
Olanzapine: Effective Symptom Control for Schizophrenia and Bipolar Disorder - Evidence-Based Review
Olanzapine stands as one of the most clinically significant atypical antipsychotics developed in the last 30 years. Initially approved by the FDA in 1996, it represented a major shift from older typical antipsychotics, offering a vastly improved side effect profile regarding extrapyramidal symptoms while maintaining potent efficacy. It’s a thienobenzodiazepine derivative, structurally related to clozapine but without the associated agranulocytosis risk that makes clozapine a last-line option. We use it primarily for schizophrenia, bipolar mania, and as an adjunct in treatment-resistant depression.
Pirfenex: Slowing Disease Progression in Idiopathic Pulmonary Fibrosis - Evidence-Based Review
Pirfenex represents one of those rare cases where an old molecule found new life through clever pharmaceutical reformulation. Originally investigated for arthritis back in the 1980s, its anti-fibrotic properties were almost an afterthought until Japanese researchers noticed something peculiar in their data. The current formulation uses a specific crystalline structure that enhances bioavailability compared to earlier versions - something that became crucial for its eventual approval. 1. Introduction: What is Pirfenex?
plavix
Plavix, known generically as clopidogrel, is a cornerstone antiplatelet medication, not a dietary supplement or medical device, prescribed to reduce the risk of heart attack and stroke in patients with acute coronary syndrome, recent MI, stroke, or established peripheral arterial disease. It works by inhibiting platelet aggregation, a critical mechanism in preventing thrombotic events. I remember when it first came out—we were all a bit skeptical. We had aspirin, which was cheap and worked well for many, so adding another agent felt like overkill to some of the older cardiologists.
